The post ASTER Consolidation Hits Critical Point: Breakout at $0.81? appeared on BitcoinEthereumNews.com. ASTER is in its longest consolidation since the $0.90–$The post ASTER Consolidation Hits Critical Point: Breakout at $0.81? appeared on BitcoinEthereumNews.com. ASTER is in its longest consolidation since the $0.90–$

ASTER Consolidation Hits Critical Point: Breakout at $0.81?

  • ASTER is in its longest consolidation since the $0.90–$1.00 zone, with local support still holding firm.
  • Analyst Ardi expects a liquidity sweep above range highs before any real breakout attempt toward $0.81.
  • A break below local support could send ASTER back to the prior breakout zone for a liquidity retest.

Crypto analyst Ardi is watching ASTER closely. He recently flagged the token’s ongoing consolidation as its longest since the $0.90 to $1.00 zone. 

According to him, local support remains intact. As long as it holds, the breakout still favors the upside. Per CoinGecko, ASTER is currently trading at $0.7273, up 3.60% in the last 24 hours.

ASTER Forms Its Longest Consolidation Range in Recent History

Ardi shared a technical breakdown on social media, noting that ASTER has been compressing inside a well-defined rectangular range. This follows a strong impulsive rally. 

Price is sitting above uptrend support, inside a local range, and below key resistance at $0.78 to $0.81. That kind of structure usually signals a pause before the next move, not a reversal.

The analyst also noted that a clear minor high has formed within the local range. That detail matters. It creates liquidity above current price levels, giving the market a target to sweep before any real breakout attempt begins.

Liquidity Sweep Could Come First Before Any Real Move

Ardi does not expect a clean breakout. His view is that the first move will likely be a wick sweep above the range highs. Breakout traders enter longs. 

The market rejects the move. Stops get triggered, and price falls back into the range.

This is a well-known liquidity grab pattern. It traps late buyers and shakes out weak hands. After that flush, Ardi expects price to regroup and attempt a genuine push higher.

Measured Move Points to $0.81 as the Key Target

The $0.81 level keeps coming up for a reason. Ardi points out that the measured move of the rectangle projects right into that area. The height of the range, extended upward from the breakout point, aligns with the same resistance zone the chart has already flagged.

That confluence makes $0.81 a technically valid target. It combines measured move theory, prior horizontal resistance, and a known reaction zone. Ardi puts the target at $0.80 to $0.81 based on that overlap.

ASTER also recorded a 24-hour trading volume of $122,823,734, reflecting strong market participation during this consolidation phase.

What Happens If Local Support Breaks

Ardi is clear about the bearish alternative. If local support fails to hold, the setup changes quickly. He expects the price to fall back toward the prior breakout zone for a liquidity retest. That green uptrend support zone would then become the next area of interest.

He does not frame this as a trend failure. It would be a deeper reset, not a collapse. The market would simply be seeking fresh demand before any continuation attempt. 

But for now, the primary scenario remains bullish as long as structure holds and local support stays intact.

Source: https://www.livebitcoinnews.com/aster-consolidation-hits-critical-point-breakout-at-0-81/

Market Opportunity
Aster Logo
Aster Price(ASTER)
$0.7211
$0.7211$0.7211
-0.27%
USD
Aster (ASTER) Live Price Chart
Disclaimer: The articles reposted on this site are sourced from public platforms and are provided for informational purposes only. They do not necessarily reflect the views of MEXC. All rights remain with the original authors. If you believe any content infringes on third-party rights, please contact service@support.mexc.com for removal. MEXC makes no guarantees regarding the accuracy, completeness, or timeliness of the content and is not responsible for any actions taken based on the information provided. The content does not constitute financial, legal, or other professional advice, nor should it be considered a recommendation or endorsement by MEXC.

You May Also Like

And the Big Day Has Arrived: The Anticipated News for XRP and Dogecoin Tomorrow

And the Big Day Has Arrived: The Anticipated News for XRP and Dogecoin Tomorrow

The first-ever ETFs for XRP and Dogecoin are expected to launch in the US tomorrow. Here's what you need to know. Continue Reading: And the Big Day Has Arrived: The Anticipated News for XRP and Dogecoin Tomorrow
Share
Coinstats2025/09/18 04:33
Non-Opioid Painkillers Have Struggled–Cannabis Drugs Might Be The Solution

Non-Opioid Painkillers Have Struggled–Cannabis Drugs Might Be The Solution

The post Non-Opioid Painkillers Have Struggled–Cannabis Drugs Might Be The Solution appeared on BitcoinEthereumNews.com. In this week’s edition of InnovationRx, we look at possible pain treatments from cannabis, risks of new vaccine restrictions, virtual clinical trials at the Mayo Clinic, GSK’s $30 billion U.S. manufacturing commitment, and more. To get it in your inbox, subscribe here. Despite their addictive nature, opioids continue to be a major treatment for pain due to a lack of effective alternatives. In an effort to boost new drugs, the FDA released new guidelines for non-opioid painkillers last week. But making these drugs hasn’t been easy. Vertex Pharmaceuticals received FDA approval for its non-opioid Journavx in January, then abandoned a next generation drug after a failed clinical trial earlier this summer. Acadia similarly abandoned a promising candidate after a failed trial in 2022. One possible basis for non-opioids might be cannabis. Earlier this year, researchers at Washington University at St. Louis and Stanford published a study showing that a cannabis-derived compound successfully eased pain in mice with minimal side effects. Munich-based pharmaceutical company Vertanical is perhaps the furthest along in this quest. It is developing a cannabinoid-based extract to treat chronic pain it hopes will soon become an approved medicine, first in the European Union and eventually in the United States. The drug, currently called Ver-01, packs enough low levels of cannabinoids (including THC) to relieve pain, but not so much that patients get high. Founder Clemens Fischer, a 50-year-old medical doctor and serial pharmaceutical and supplement entrepreneur, hopes it will become the first cannabis-based painkiller prescribed by physicians and covered by insurance. Fischer founded Vertanical, with his business partner Madlena Hohlefelder, in 2017, and has invested more than $250 million of his own money in it. With a cannabis cultivation site and drug manufacturing plant in Denmark, Vertanical has successfully passed phase III clinical trials in Germany and expects…
Share
BitcoinEthereumNews2025/09/18 05:26
Rising Altcoin Inflows Signal Potential Market Sell-Off: CryptoQuant

Rising Altcoin Inflows Signal Potential Market Sell-Off: CryptoQuant

        Highlights:  Inflows of altcoins in exchanges have surged by 22% in early 2026. An increase in deposits indicates a growing sell-side pressure. The 
Share
Coinstats2026/02/22 02:03